XERA 3 Deutschland GmbH

About XERA 3 Deutschland

XERA 3 Deutschland GmbH is a medical technology company based in Hamburg specializing in innovative breast cancer screening. The company distributes the multifrequency mammography screening system xeraskopie®, a procedure based on bioimpedance spectroscopy for breast cancer screening and risk assessment. During the examination, impedances of the breast tissue are measured within a few minutes using special applicators and highly sensitive electrodes; the results provide information about tissue structures and define disease risks. The procedure is radiation-free, pain-free and performed without compression of the breast, and according to the provider it can also be used on dense breast tissue and in all age groups. The average examination duration is about eight minutes. Target groups are women in Germany, especially high-risk patients; the company also addresses practices that offer the procedure.

Site

Hamburg

Processes

Bioimpedance spectroscopy (xeraskopie®), Sales of multifrequency mammography screening devices (xeraskopie®), Bioimpedance spectroscopy for breast cancer screening and risk assessment

Materials

Bioimpedance spectroscopy (xeraskopie®)

Founded

2011-05-24

Employees

2–10

Industries

Medical Technology, Health Diagnostics, Oncology, Medical Technology (Manufacture of Irradiation and Electrotherapy Equipment)

1. 01

   Sales of multifrequency mammography screening devices

2. 02

   Performance of the bioimpedance measurement (xeraskopie®)

3. 03

   Evaluation of the impedance data for risk assessment

4. 04

   Referral to further treatment procedures in case of abnormalities

Procedures & Technology

Location

Processes & technical limits

History

1. 2011

   Foundation of XERA 3 Deutschland GmbH on 24.05.2011 in Hamburg with a share capital of 60.000 € (HRB 118641, Hamburg Local Court).